These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28915690)

  • 1. Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction.
    Wang P; Que W; Li H; Yan L; Fu Z; Ye Q; Chen G; Dou K; Lu S; Yang Z; Zhu Z; Peng Z; Zhong L
    Oncotarget; 2017 Aug; 8(34):57505-57515. PubMed ID: 28915690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Pageaux GP; Rostaing L; Calmus Y; Duvoux C; Vanlemmens C; Hardgwissen J; Bernard PH; Barbotte E; Vercambre L; Bismuth M; Puche P; Navarro F; Larrey D
    Liver Transpl; 2006 Dec; 12(12):1755-60. PubMed ID: 17133564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
    He L; Deng J; Yang B; Jiang W
    Clin Nephrol; 2018 May; 89(5):336-344. PubMed ID: 29292693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
    Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
    Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
    Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
    Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
    Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
    Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
    Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
    Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
    Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
    Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
    Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
    Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
    Cicinnati VR; Yu Z; Klein CG; Sotiropoulos GC; Saner F; Malagó M; Frilling A; Gerken G; Broelsch CE; Beckebaum S
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1195-208. PubMed ID: 17944734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.